Investigation of *Chlamydia pneumoniae* Infection in Patients With Multiple Sclerosis: A Case-Control Study

Sima Kazemi1,2, Bahareh Lashtoo Aghaee1,3, Ali Reza Soltanian4, Mehrdokht Mazdeh5, Mohammad Taheri6, Mohammad Yousef Alikhani2,6*

1Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
2Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
3Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
4Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
5Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
6Brucellosis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.

**Abstract**

**Background:** *Chlamydia pneumoniae* has currently been proposed to be involved in multiple sclerosis (MS) pathogenesis. The aim of this study was to evaluate the serum level of anti-*C. pneumoniae* immunoglobulin G (IgG) in patients with MS compared to the control group, which may be helpful in further understanding of MS etiology.

**Methods:** The serum was obtained from 66 people with MS and 20 healthy people as patient and control groups, respectively. Serums were matched to the patient’s age, gender, and place of residence. Finally, anti-*C. pneumoniae* IgG was measured by a sandwich enzyme-linked immunosorbent assay (ELISA).

**Results:** Sixty-six patients (25 men and 41 women within the age range of 17-56 years and mean ± SD of 38.3 ± 9.66) were enrolled in this study. The mean serum anti-*C. pneumoniae* IgG of patients with MS (35.53 ± 9.56) with MS and 20 control subjects (8 men and 12 women with the age range of 25-56 and mean ± SD of 38.1 ± 9.66) were enrolled in this study. The mean serum anti-*C. pneumoniae* IgG of patients with MS (28.82 ± 33.54 RU/mL) was compared with that of the control group (4.075 ± 6.691 RU/mL) and a statistically significant difference was observed in this regard (P < 0.001).

**Conclusions:** In general, there was a significant relationship between the incidence of MS and the *C. pneumoniae* infection. However, the actual involvement of *C. pneumoniae* in MS is still a matter of debate and needs to be clarified in further studies (e.g., by creating animal models and conducting trial tests).

**Keywords:** *Chlamydia pneumoniae*, Multiple sclerosis, ELISA

**Background**

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) with myelin destructions induced by the immune system (1). The clinical symptoms of MS are highly variable and can include impaired vision and abnormalities in the motor and coordination systems (2). Four general forms for this disease include primary progressive, secondary progressive, relapsing-remitting, and progressive relapsing (3). The disease typically occurs at the age of 18 to 40 and almost in women twice as much as men (4). The incidence of MS in different regions of Iran varies from 5.3 to 74.28 per 100 000 people (5-8). Nevertheless, a study showed that the prevalence of MS was 61 patients per 100 000 people in Hamadan (9). Although the cause of this disease is still unknown, several factors such as genetics, environmental factors, and infectious agents (bacteria and viruses) are known in the etiology of this disease (10). Bacteria as one of the most important infectious agents in human societies can be one of the factors contributing to MS (11). The potential of bacteria in molecular mimicry as an effective mechanism for inducing MS is more than that of viruses (12). Some studies evaluated the role of *Acinetobacter*, *Helicobacter pylori*, Spirochetes, *Campylobacter*, *Mycobacteria*, and *Chlamydia pneumoniae* in the etiology of MS (13-18). *C. pneumoniae* is a gram-negative, obligate intracellular, and non-motile bacterium which causes acute respiratory diseases like pneumonia (19). In addition, *C. pneumoniae* causes other diseases such as atherosclerosis, asthma, encephalitis, and arthritis (20). There are few studies on the association between MS and *C. pneumoniae* infection. Accordingly, the present study aimed to estimate the serum level of immunoglobulin G (IgG) anti-*C. pneumoniae* antibodies in MS patients compared with the control subjects. It is hoped that the findings of this study help further understand the etiology of MS.
Methods
This study included 66 patients with MS who were admitted to the Neurology Department at Farshchian hospital of Hamadan province, Iran between December 2017 and August 2018. This disease was diagnosed by specialized neurologists based on McDonald’s criteria (21) and 20 healthy people were matched with patients’ age, gender, and place of residence.

Three milliliters of blood samples were collected from all individuals in the study and then were centrifuged at 3000 rpm for 7 minutes. The sera were stored at -70°C until further analysis. Then, C. pneumoniae IgG was measured by the ELISA kit (Euroimmun, Germany) according to the manufacturer’s instructions.

Statistical Analysis
Data analysis was performed using SPSS software, version 16. P values less than 0.05 were considered statistically significant.

Results
In general, 66 patients (25 men and 41 women in the age range of 17-56 years and with the mean±SD of 35.53±9.56) with MS and 20 control subjects (8 men and 12 women within the age range of 25-56 and the mean±SD of 38.3±9.66) were enrolled in this study. Table 1 presents the anti-C. pneumoniae IgG and demographic characteristics in patients with MS and healthy subjects.

The mean serum anti-C. pneumoniae IgG of patients with MS (28.82 ± 33.54 RU/mL) was compared with that of the control group (6.69 ± 4.07 RU/mL) indicating a statistically significant difference (P<0.001).

Discussion
MS is considered a chronic inflammatory disease that affects the CNS and causes several neurological disorders (22). Thus, this study investigated the relationship between MS and C. pneumoniae infection in a sample of the Iranian population. Although no evidence is available regarding the main cause of the disease, some epidemiologic studies confirmed the role of genetic factors and the environment in the development of the disease (23-26). Therefore, the role of infectious agents as environmental factors is important from this perspective (11). C. pneumoniae is one of the most important organisms and its role has been recently emphasized in MS. Due to the inability of the host to complete the elimination of C. pneumoniae, this bacterium can lead to persistent infections (27).

Monocytes pass the bacterium from the blood-brain barrier and enter it into the CNS, which ultimately causes inflammation. Therefore, it can play a role in the development of MS (28). Several studies have confirmed the association between MS and C. pneumoniae infection. In this study, it was found that anti-C. pneumoniae IgG in MS patients was significantly higher compared to the control group. The number of patients and the control group in this study was 66 (25 men and 41 women) and 20 (8 men and 12 women), respectively. In addition, the mean age of the patient and control groups was 35.53 and 38.3, respectively. In contrast to our study, Ramroodi et al showed that there is no direct correlation between MS and C. pneumoniae infection. In this study, the number of patients and healthy people was 80 and their average age was 36.63 and 36.53, respectively. Further, the mean age was similar to that of our study (29). In another study, Khaliel and Abbas also found no significant relationship between C. pneumoniae infection and MS disease. The mean age of people with MS and healthy people was 34.5 and 34.7, respectively, and the number of patient and control groups was 60 (25 men and 35 women) and 30 (8 men and 22 women), respectively (30). Similarly, Aghaei et al demonstrated no association between MS and C. pneumoniae in Iranian people. One reason for the discrepancy between the findings of this study and those of our study could be the difference in geographical areas. The number of patients and the control group in that study was 85 (18 men and 67 women) and 50 (12 men and 38 women), respectively, and their mean age was reported to be 33.8 and 33.9. Some studies (30-31) were similar to our study in that the number of people in the control group was more than that in the patients group (31). Munger et al found that there was a positive association between C. pneumoniae infection

| Factors                      | Case Group (n=66) | Control Group (n=20) | P Value |
|------------------------------|------------------|----------------------|---------|
| Age (mean ± SD)              | 35.53 ± 9.56     | 38.3 ± 9.66          |         |
| Range (years)               | 17-56            | 25-56                |         |
| Gender                       |                  |                      |         |
| Men, No. (%)                | 25 (37.9)        | (40) 8               |         |
| Women, No. (%)              | 41 (62.1)        | 12 (60)              |         |
| IgG anti-Chlamydia pneumonia (>22 RU/mL) (mean ± SD) | 28.82 ± 33.54 | 4.075 ± 6.691 | < 0.001 |

Note: MS: multiple sclerosis; SD: standard deviation; IgG: immunoglobulin G.
and the progression of MS (32), which is in line with the findings of our study. Likewise, Siriam et al showed that *C. pneumoniae* infection in MS patients was more than that of the control group (20). Another study concluded that *C. pneumoniae* infection was more frequent in MS patients compared to the healthy population (33). An experimental model of MS was done on rats and the results showed that the peptides of this bacterium are similar to myelin (34). Further, Layh-Schmitt et al reported that *C. pneumoniae* can be found in the cerebrospinal fluid of MS patients (35). Currently, *C. pneumoniae* has been proposed to be involved in the pathogenesis of MS, and thus more studies with higher sample sizes are needed to further demonstrate the role of *C. pneumoniae* in the development of MS. However, the actual involvement of *C. pneumoniae* in MS is still a matter of debate and needs further clarification in future studies (e.g., by the creation of animal models).

**Conflict of Interests**

None.

**Ethical Approval**

This study was confirmed by the Ethics Committee of Hamadan University of Medical Sciences (Ethical approval code: IR.UMSHA.REC.1396.187).

**References**

1. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409-16. doi: 10.2174/157015911796557911.
2. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727-39. doi: 10.1016/s1474-4422(10)70094-6.
3. Hemmer B, Arcelhos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002;3(4):291-301. doi: 10.1038/nrn784.
4. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2(4):201-11. doi: 10.1038/ncpneuro0154.
5. Etemadifar M, Janghborani M, Shayannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology. 2006;27(1):39-44. doi: 10.1159/000092435.
6. Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler. 2011;17(8):1022-7. doi: 10.1177/1352458511401460.
7. Tolou-Ghahrami Z. Preliminary study of differences between prevalence of multiple sclerosis in Isfahan and its rural provinces. Arch Neurosci. 2015;2(2):e60043. doi: 10.5812/archneurosci.29034.
8. Zahiri M, Gahvehdi H, Shafee M, Kazeminejad SR, Alavi SM. Analysis of HLA-DQ61*0602 in multiple sclerosis patients in Khouzestan province, Iran. Arch Iran Med. 2015;18(10):698-702.
9. Mazdeh M, Khazaei M, Hashemi-Firoozu N, Ghasian M. Frequency of multiple sclerosis (MS) among relatives of MS patients in Hamadan society, Iran. Avicenna J Neuro Psycho Physiology. 2016;3(1):1-5. doi: 10.17795/ajnpmp-38613.
10. Zawada M. [Potential pathogens in multiple sclerosis (MS)]. Postepy Hig Med Dosw (Online). 2012;66:758-70. doi: 10.5604/17322693.1015041.
11. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2003;21:683-747. doi: 10.1146/annurev.immunol.21.032802.120350.
12. Kurtzke JF. Hyllested K. Multiple sclerosis in the Faroe Islands. Ill. An alternative assessment of the three epideimics. Acta Neurol Scand. 1987;76(5):317-39. doi: 10.1111/j.1600-0404.1987.tb03590.x.
13. Chmielewska-Badory J, Cisak E, Duktiewicz J. Lyme borreliosis and multiple sclerosis: any connection? A seroepidemi study. Ann Agric Environ Med. 2000;7(2):141-3.
14. Cossu D, Cocco E, Paccagnini D, Masala S, Ahmed N, Frau J, et al. Association of *Mycobacterium avium* subsp. *paratuberculosis* with multiple sclerosis in Sardinian patients. PLoS One. 2011;6(4):e18482. doi: 10.1371/journal.pone.0018482.
15. Gavalas E, Kountouras J, Boziki M, Zavos C, Polyzos SA, Vlachaki E, et al. Relationship between *Helicobacter pylori* infection and multiple sclerosis. Ann Gastroenterol. 2015;28(3):353-6.
16. Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, Kim YV, et al. Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun. 2005;73(2):1014-22. doi: 10.1128/iai.73.2.1014-1022.2005.
17. Hughes LE, Bonell S, Natt RS, Wilson C, Twiana H, Ebringer A, et al. Antibody responses to *Acinetobacter spp.* and *Pseudomonas aeruginosa* in multiple sclerosis: prospects for diagnosis using the myelin-acinetobacter-neurofilament antibody index. Clin Diagn Lab Immunol. 2001;8(6):1181-8. doi: 10.1128/cdli.8.6.1181-1188.2001.
18. Maida E. Immunological reactions against *Mycoplasma pneumoniae* in multiple sclerosis: preliminary findings. J Neurol. 1983;229(2):103-11. doi: 10.1007/bf00313449.
19. Cook PJ, Honeybourne D. *Chlamydia pneumoniae*. J Antimicrob Chemother. 1994;34(6):859-73. doi: 10.1093/jac/34.6.859.
20. Siriam S, Mitchell W, Stratton C. Multiple sclerosis associated with *Chlamydia pneumoniae* infection of the CNS. Neurology. 1998;50(2):571-2. doi: 10.1212/wnl.50.2.571.
21. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. doi: 10.1002/ana.22366.
22. Al-Omaishi J, Bashir R, Gendelman HE. The cellular immunology of multiple sclerosis. J Leukoc Biol. 1999;65(4):444-52. doi: 10.1002/jlb.65.4.444.
23. Javan MR, Seyfiizadeh N, Aslani S, Farhoodi M, Babaloo Z. Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis. Am J Clin Exp Immunol. 2014;3(2):91-6.
24. Milo R, Kahana E. Multiple sclerosis: genetics and the environment. Autoimmun Rev. 2010;9(5):A387-94. doi: 10.1016/j.autrev.2009.11.010.
25. Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011;2:334. doi: 10.1038/ncomms1333.
26. Orton SM, Morris AP, Herrera BM, Ramagopalan SV, Lincoln MR, Chao MJ, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr. 2008;88(2):441-7. doi: 10.1093/ajcn/88.2.441.
27. Fainardi E, Castellazzi M, Seraceni S, Granieri E, Contini C. Under the microscope: focus on *Chlamydia pneumoniae* infection and multiple sclerosis. Curr Neurovasc Res.
28. Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. *Chlamydiaphila pneumoniae* infection and its role in neurological disorders. Interdiscip Perspect Infect Dis. 2010;2010:273573. doi: 10.1155/2010/273573.

29. Ramroodi N, Sanadgol N. Relationship between Chlamydia pneumonia infection and susceptibility of multiple sclerosis (MS) in southeast of Iran: a case-control study. Int J Med Med Sci. 2015;7(7):125-9. doi: 10.5897/ijmms2015.1066.

30. Khaliel AH, Abbas AA. Chlamydia pneumoniae: the potential cause of multiple sclerosis. Iraq J Med Sci. 2016;14(2):131-6.

31. Aghaei M, Ashtari F, Bahar M, Falahian MR. *Chlamydia pneumoniae* seropositivity in Iranian patients with multiple sclerosis: a pilot study. Neurol Neurochir Pol. 2011;45(2):128-31. doi: 10.1016/s0028-3843(14)60023-2.

32. Munger KL, DeLorenze GN, Levin LJ, Rubertone MV, Vogelman JH, Peck CA, et al. A prospective study of *Chlamydia pneumoniae* infection and risk of MS in two US cohorts. Neurology. 2004;62(10):1799-803. doi: 10.1212/01.wnl.0000125193.58601.2c.

33. Parratt J, Tavendale R, O’Riordan J, Parratt D, Swingler R. *Chlamydia pneumoniae*-specific serum immune complexes in patients with multiple sclerosis. Mult Scler. 2008;14(3):292-9. doi: 10.1177/1352458507083188.

34. Lenz DC, Lu L, Conant SB, Wolf NA, Gérard HC, Whittum-Hudson JA, et al. A *Chlamydia pneumoniae*-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol. 2001;167(3):1803-8. doi: 10.4049/jimmunol.167.3.1803.

35. Layh-Schmitt G, Bendl C, Hildt U, Dong-Si T, Jüttler E, Schnitzler P, et al. Evidence for infection with *Chlamydia pneumoniae* in a subgroup of patients with multiple sclerosis. Ann Neurol. 2000;47(5):652-5.